close

Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company's products in development includes Nicotine Conjugate Vaccine, a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse; and Pentavalent S.aureus Vaccine, a pentavalent vaccine designed to prevent S.aureus infections, including those infections caused by antibiotic-resistant strains of S.aureus. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland. The company was founded in 1967 and is headquartered in Rockville, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.85
Volume	241670
Volume Avg	221469
52 Week High	5.90
52 Week Low	1.50
PE	N/A
PE (group average)	39
EPS Year	-0.21
EPS change Q/Q	-1000%
EPS change Q/Q Yr ago	-54.55%
EPS change Q/Q next Q est	-100%
EPS change Y/Y	1000%
REV change Q/Q	124.39%
REV change Q/Q Yr ago	-32.85%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%